Key Events This Week
31 Aug: New 52-week high at Rs.1,692.00
1 Sep: All-time high reached Rs.1,706.7
1 Sep: Sharp open interest surge amid mixed price signals
4 Sep: Week closes at Rs.1,653.30 (+0.20%)

Aurobindo Pharma Ltd. is Rated Hold by MarketsMOJO
2026-09-04 10:10:46Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 September 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Aurobindo Pharma Sees Sharp Open Interest Surge Amid Mixed Market Signals
2026-09-01 12:00:07Aurobindo Pharma Ltd. has witnessed a significant 21.6% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this, the stock underperformed its sector and traded in a narrow range close to its 52-week high, reflecting a complex interplay of bullish and cautious sentiments among traders.
Read full news article
Broad-Based Technical Strength Lifts Aurobindo Pharma Ltd. to 52-Week High of Rs 1706.7
2026-09-01 09:35:33With a remarkable 64.8% gain over the past year, Aurobindo Pharma Ltd. surged to a fresh 52-week high of Rs 1706.7 on 1 Sep 2026, outpacing the Sensex which declined by 4.2% over the same period. This milestone underscores the stock’s sustained momentum amid a broader market that has been under pressure.
Read full news article
Aurobindo Pharma Sees Sharp Open Interest Surge Amidst Bullish Momentum
2026-08-31 14:00:07Aurobindo Pharma Ltd. has witnessed a notable surge in open interest in its derivatives segment, coinciding with robust price gains and sustained bullish momentum. The pharmaceutical giant’s stock hit a fresh 52-week high of Rs 1,684.7 on 31 Aug 2026, supported by a 13.3% increase in open interest, signalling heightened market participation and potential directional bets by traders.
Read full news article









